Key result
Dabigatran and rivaroxaban were associated with a significantly lower risk of death compared to warfarin in patients with AF and VHD (HR 0.71; 95% CI 0.52-0.98 and HR 0.68; 95% CI 0.49-0.95).
Why the study?
Do dabigatran or rivaroxaban reduce mortality, ischemic stroke, major bleeding, and myocardial infarction compared to warfarin in Medicare beneficiaries with atrial fibrillation and valvular heart disease?
Population
103,733 Medicare beneficiaries enrolled between 2011 and 2013 with newly diagnosed atrial fibrillation…
Comparison
Dabigatran or rivaroxaban vs Warfarin
Design
Cohort
Authors
Loading...
Associated with lower mortality than warfarin in AF with VHD; leaves open confirmation in randomized trials.
Cohort (n=103,733)
Yes
Do dabigatran or rivaroxaban reduce mortality, ischemic stroke, major bleeding, and myocardial infarction compared to warfarin in Medicare beneficiaries with atrial fibrillation and valvular heart disease?
Hazard Ratio: 0.71 (95% CI 0.52–0.98)
p-value: p=0.038
In Medicare beneficiaries with atrial fibrillation and valvular heart disease, dabigatran and rivaroxaban are associated with reduced mortality and non-gastrointestinal bleeding compared to warfarin.
Briasoulis et al. (2018) conducted a cohort in Atrial fibrillation and valvular heart disease (n=103,733). Dabigatran and rivaroxaban vs. Warfarin was evaluated on All-cause mortality (HR 0.71, 95% CI 0.52-0.98, p=0.038). Dabigatran and rivaroxaban were associated with a significantly lower risk of death compared to warfarin in patients with AF and VHD (HR 0.71; 95% CI 0.52-0.98 and HR 0.68; 95% CI 0.49-0.95).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: